Disease · MONDO_1010128
peritonitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. peritonitis. Diseases, record MONDO_1010128. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_1010128
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs24
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CEFTAZIDIME | CHEMBL44354 | Small molecule | Approval | DailyMed and PMDA | 10 | 0 | 0 | Drugs and targets |
| AMIKACIN SULFATE | CHEMBL4208954 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| ANIDULAFUNGIN | CHEMBL264241 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| AVIBACTAM SODIUM | CHEMBL2107817 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| CEFTOLOZANE SULFATE | CHEMBL1213250 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| CLINDAMYCIN PHOSPHATE | CHEMBL3184512 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PIPERACILLIN SODIUM | CHEMBL1200820 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| TAZOBACTAM | CHEMBL404 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| TAZOBACTAM SODIUM | CHEMBL1439 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| TIGECYCLINE | CHEMBL376140 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 24
See all 24 drugsTargets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| PLAT | Tissue-type plasminogen activator | 1 | Tissue-type plasminogen activator exogenous protein | Phase 1 | https://conductscience.org/library/genes/5327 | Drugs and targets |
Trials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01793688 | Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration - | 982 | 2017-04-26 | Pneumonia, Lung Abscess, Peritonitis | AMPICILLIN SODIUM, SULBACTAM SODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT02787057 | Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis | Not applicable | 80 | 2020-03-26 | Peritoneal Dialysis Associated Peritonitis | MOXIFLOXACIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01670435 | Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance | 3,274 | Infection | CIPROFLOXACIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT01690559 | Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution | 704 | Infection | CIPROFLOXACIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT04168099 | Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis | Phase 3 | 60 | Spontaneous Bacterial Peritonitis | CEFOTAXIME, GEMIFLOXACIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06426212 | Use of Teicoplanin on a Three-weekly Administration in the Infectious Diseases Unit | 40 | Comparison of Teicoplanin Used Three Times a Week in DSIs vs NDISs | TEICOPLANIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT01705756 | Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever | Phase 3 | 25 | Familial Mediterranean Fever | ANAKINRA | Its record names the disease | ClinicalTrials.gov | |
| NCT00497744 | A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis | 6 | Peritonitis | CEFEPIME | Its record names the disease | ClinicalTrials.gov | ||
| NCT01478698 | The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients | Phase 1 | 5 | Peritoneal Dialysis, Peritoneal Dialysis, Continuous Ambulatory | DESOXYRIBONUCLEASE | Its record names the disease | ClinicalTrials.gov | |
| NCT04624451 | Evaluation of Intravenous Dalbavancin for Peritonitis | 2 | Peritonitis, Peritonitis Bacterial | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Study Group vs Control Group: Complete Cure Rate | 31 of 40 | 32 of 40 | 80 | NCT02787057 | Trial comparisons |
| Study Group vs Control Group: Secondary Treatment Failure Rate | 4 of 40 | 5 of 40 | 80 | NCT02787057 | Trial comparisons |
| Study Group vs Control Group: Primary Response Rate | 27 of 40 | 32 of 40 | 80 | NCT02787057 | Trial comparisons |
| Study Group vs Control Group: Primary Treatment Failure Rate | 13 of 40 | 8 of 40 | 80 | NCT02787057 | Trial comparisons |
| Study Group vs Control Group: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT02787057 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 27860460 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_1010128
GET https://conductscience.org/api/diseases/v1/MONDO_1010128/drugs?page=2